Agenus Inc. Consolidated Net Income/Loss

Consolidated Net Income/Loss of AGEN for past 10 years: annual, quarterly and twelve month trailing (TTM) including Consolidated Net Income/Loss growth rates and interactive chart.


Highlights and Quick Summary

  • Consolidated Net Income/Loss for the quarter ending June 29, 2020 was $-48.2 Million (a 6.57% increase compared to previous quarter)
  • Year-over-year quarterly Consolidated Net Income/Loss increased by 4.25%
  • Annual Consolidated Net Income/Loss for 2019 was $-112 Million (a -31.15% decrease from previous year)
  • Annual Consolidated Net Income/Loss for 2018 was $-162 Million (a 34.26% increase from previous year)
  • Annual Consolidated Net Income/Loss for 2017 was $-121 Million (a -4.96% decrease from previous year)
  • Twelve month Consolidated Net Income/Loss ending June 29, 2020 was $-171 Million (a -2.08% decrease compared to previous quarter)
  • Twelve month trailing Consolidated Net Income/Loss increased by 31.71% year-over-year
Trailing Consolidated Net Income/Loss for the last four month:
29 Jun '20 30 Mar '20 30 Dec '19 29 Sep '19
$-171 Million $-174 Million $-112 Million $-130 Million
Visit stockrow.com/AGEN for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Consolidated Net Income/Loss of Agenus Inc.

Most recent Consolidated Net Income/Lossof AGEN including historical data for past 10 years.

Interactive Chart of Consolidated Net Income/Loss of Agenus Inc.

Agenus Inc. Consolidated Net Income/Loss for the past 10 Years (both Annual and Quarterly)

(All values are in $ million)

Year Q1 Q2 Q3 Q4 Fiscal Year
2020 $-48.24 $-45.27
2019 $-30.85 $-46.28 $-51.87 $17.44 $-111.56
2018 $-48.85 $-33.73 $-25.2 $-54.26 $-162.04
2017 $-35.03 $-36.84 $-31.71 $-17.1 $-120.69
2016 $-26.12 $-40.77 $-28.32 $-31.78 $-127.0
2015 $-15.61 $-13.12 $-40.41 $-18.74 $-87.88
2014 $-25.98 $-8.11 $-8.04 $-0.36 $-42.49
2013 $-5.78 $-7.32 $-11.14 $-5.84 $-30.07
2012 $-5.44 $-5.73 $-6.92 $6.77 $-11.32
2011 $-6.02 $-5.53 $-5.76 $-5.96 $-23.28
2010 $-2.42 $-5.71 $-4.97 $-8.81 $-21.91
2009 $1.86 $-10.61 $-30.32

Business Profile of Agenus Inc.

Sector: Medical
Industry: Drugs
Agenus Inc., a clinical-stage immuno-oncology company, discovers, manufactures, and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody discovery platform for the identification of fully-human and humanized monoclonal antibodies; and display technologies. It develops vaccine programs, including Prophage vaccine candidate; AutoSynVax, a synthetic neo-antigen; PhosPhoSynVax, a vaccine candidate designed to induce immunity against a class of tumor specific neo-epitopes; and QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company also develops CTLA-4 and PD-1 antagonists which is in clinical trial phase I for the dose escalation study; AGEN2373, an anti-CD137 monospecific antibody which is in Phase 1 clinical trial; AGEN1223, a novel bispecific antibody designed to deplete regulatory T cells which is in a Phase 1 clinical trial; GS-1423, a tumor microenvironment conditioning anti-CD73/TGFß TRAP bi-functional antibody which is in Phase 1 clinical trial; and TIGIT antibodies. In addition, it engages in the development of INCAGN1876, an anti-GITR monospecific antibody; INCAGN1949, an anti-OX40 monospecific antibody; INCAGN2390, an anti-TIM-3 monospecific antibody; INCAGN2385, an anti-LAG-3 monospecific antibody; and MK-4830, a monospecific antibody targeting ILT4. Agenus Inc. has collaboration agreements with Incyte Corporation, Merck Sharpe & Dohme, and Recepta Biopharma SA.; and collaboration with Gilead Sciences, Inc. to develop immuno-oncology therapies. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.